Literature DB >> 34298969

Epigenetic Regulation of microRNAs in Cancer: Shortening the Distance from Bench to Bedside.

María J Pajares1,2, Ester Alemany-Cosme3, Saioa Goñi1, Eva Bandres2,4, Cora Palanca-Ballester3, Juan Sandoval3,5.   

Abstract

Cancer is a complex disease involving alterations of multiple processes, with both genetic and epigenetic features contributing as core factors to the disease. In recent years, it has become evident that non-coding RNAs (ncRNAs), an epigenetic factor, play a key role in the initiation and progression of cancer. MicroRNAs, the most studied non-coding RNAs subtype, are key controllers in a myriad of cellular processes, including proliferation, differentiation, and apoptosis. Furthermore, the expression of miRNAs is controlled, concomitantly, by other epigenetic factors, such as DNA methylation and histone modifications, resulting in aberrant patterns of expression upon the occurrence of cancer. In this sense, aberrant miRNA landscape evaluation has emerged as a promising strategy for cancer management. In this review, we have focused on the regulation (biogenesis, processing, and dysregulation) of miRNAs and their role as modulators of the epigenetic machinery. We have also highlighted their potential clinical value, such as validated diagnostic and prognostic biomarkers, and their relevant role as chromatin modifiers in cancer therapy.

Entities:  

Keywords:  DNA methylation; biomarkers; cancer; clinical applications; epigenetics; microRNAs

Year:  2021        PMID: 34298969     DOI: 10.3390/ijms22147350

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  6 in total

Review 1.  Epigenetic modification and BRAF gene mutation in thyroid carcinoma.

Authors:  Guo Huang; Juan Chen; Jun Zhou; Shuai Xiao; Weihong Zeng; Jiliang Xia; Xi Zeng
Journal:  Cancer Cell Int       Date:  2021-12-19       Impact factor: 5.722

2.  The long noncoding RNA noncoding RNA activated by DNA damage (NORAD)-microRNA-496-Interleukin-33 axis affects carcinoma-associated fibroblasts-mediated gastric cancer development.

Authors:  Chaoqun Huang; Jiuyang Liu; Liang He; Fubing Wang; Bin Xiong; Yan Li; Xiaojun Yang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 3.  Crucial Roles of miR-625 in Human Cancer.

Authors:  Menggang Zhang; Fei Xiong; Shuijun Zhang; Wenzhi Guo; Yuting He
Journal:  Front Med (Lausanne)       Date:  2022-03-04

Review 4.  Noncoding RNAs in Cardiac Hypertrophy and Heart Failure.

Authors:  Peilei Lu; Fan Ding; Yang Kevin Xiang; Liying Hao; Meimi Zhao
Journal:  Cells       Date:  2022-02-23       Impact factor: 6.600

Review 5.  Microbiomes, Epigenomics, Immune Response, and Splicing Signatures Interplay: Potential Use of Combination of Regulatory Pathways as Targets for Malignant Mesothelioma.

Authors:  Botle Precious Setlai; Zilungile Lynette Mkhize-Kwitshana; Ravi Mehrotra; Thanyani Victor Mulaudzi; Zodwa Dlamini
Journal:  Int J Mol Sci       Date:  2022-08-12       Impact factor: 6.208

6.  Glaucocalyxin A Inhibits the Malignancies of Gastric Cancer Cells by Downregulating MDM2 and RNF6 via MiR-3658 and the SMG1-UPF mRNA Decay Pathway.

Authors:  Yanqi Liu; Ping Chen; Daqing Qi; Linhui Chen
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.